Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

NCT05287451 · View on ClinicalTrials.gov ↗

Study Summary

This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

Interventions

  • OTHER RIsk-Reducing Salpingectomy (RRS)
  • OTHER Risk-Reducing Oophorectomy-RRO
  • OTHER Risk-Reducing Salpingo-Oophorectomy-RRSO

Study Locations (9)

New York

  • Mount Sinai Health System — New York
  • Memorial Sloan Kettering Cancer Center — New York

Texas

  • Lyndon Baines Johnson General — Houston
  • M D Anderson Cancer Center — Houston

Massachusetts

  • Dana Farber Cancer Institute — Boston

Minnesota

  • Mayo Clinic — Rochester

Missouri

  • WU St Louis — St Louis

Pennsylvania

  • University of Pennsylvania — Philadelphia

Washington

  • University of Washington — Seattle

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2022-05-10
Est. Completion 2026-12-26
Phase NA

Sponsor

M.D. Anderson Cancer Center

2,992 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05287451

The ClinicalTrials.gov registry entry for NCT05287451 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,992 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions — of which RIsk-Reducing Salpingectomy (RRS) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05287451 reports 9 study locations spanning 7 distinct geographic areas — top geographies include New York, Texas, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05287451 about?

NCT05287451 is a clinical study titled "Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study". This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence

What is the current status of trial NCT05287451?

This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-05-10. Estimated completion is 2026-12-26.

What conditions does trial NCT05287451 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05287451?

The interventions under investigation include: RIsk-Reducing Salpingectomy (RRS) (OTHER), Risk-Reducing Oophorectomy-RRO (OTHER), Risk-Reducing Salpingo-Oophorectomy-RRSO (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05287451?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,992 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05287451 being conducted?

This trial has 9 study locations across Massachusetts, Minnesota, Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial